ALL |
META-ANALYSIS |
CITATIONS |
|
Benefit-Cost Summary Statistics Per Participant | ||||||
---|---|---|---|---|---|---|
Benefits to: | ||||||
Taxpayers | ($206) | Benefits minus costs | ($3,252) | |||
Participants | ($230) | Benefit to cost ratio | ($1.99) | |||
Others | ($33) | Chance the program will produce | ||||
Indirect | ($1,695) | benefits greater than the costs | 46% | |||
Total benefits | ($2,163) | |||||
Net program cost | ($1,089) | |||||
Benefits minus cost | ($3,252) | |||||
Meta-Analysis of Program Effects | ||||||||||||
Outcomes measured | Treatment age | No. of effect sizes | Treatment N | Effect sizes (ES) and standard errors (SE) used in the benefit-cost analysis | Unadjusted effect size (random effects model) | |||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|
First time ES is estimated | Second time ES is estimated | |||||||||||
ES | SE | Age | ES | SE | Age | ES | p-value | |||||
Crime Any criminal conviction according to court records, sometimes measured through charges, arrests, incarceration, or self-report. |
32 | 5 | 8683 | -0.007 | 0.039 | 33 | -0.007 | 0.039 | 41 | -0.089 | 0.239 | |
Illicit drug use disorder Clinical diagnosis of illicit drug use disorder or symptoms measured on a validated scale. When possible, we exclude cannabis/marijuana use disorder from this outcome. |
32 | 2 | 319 | 0.102 | 0.107 | 32 | 0.000 | 0.187 | 35 | 0.112 | 0.296 |
Detailed Monetary Benefit Estimates Per Participant | ||||||
Affected outcome: | Resulting benefits:1 | Benefits accrue to: | ||||
---|---|---|---|---|---|---|
Taxpayers | Participants | Others2 | Indirect3 | Total |
||
Crime | Criminal justice system | $128 | $0 | $225 | $64 | $416 |
Illicit drug use disorder | Labor market earnings associated with illicit drug abuse or dependence | ($65) | ($154) | $0 | $0 | ($220) |
Health care associated with illicit drug abuse or dependence | ($252) | ($38) | ($257) | ($126) | ($673) | |
Mortality associated with illicit drugs | ($16) | ($38) | $0 | ($1,088) | ($1,142) | |
Program cost | Adjustment for deadweight cost of program | $0 | $0 | $0 | ($545) | ($545) |
Totals | ($206) | ($230) | ($33) | ($1,695) | ($2,163) | |
Detailed Annual Cost Estimates Per Participant | ||||
Annual cost | Year dollars | Summary | ||
---|---|---|---|---|
Program costs | $889 | 2016 | Present value of net program costs (in 2023 dollars) | ($1,089) |
Comparison costs | $0 | 2016 | Cost range (+ or -) | 10% |
Benefits Minus Costs |
Benefits by Perspective |
Taxpayer Benefits by Source of Value |
Benefits Minus Costs Over Time (Cumulative Discounted Dollars) |
The graph above illustrates the estimated cumulative net benefits per-participant for the first fifty years beyond the initial investment in the program. We present these cash flows in discounted dollars. If the dollars are negative (bars below $0 line), the cumulative benefits do not outweigh the cost of the program up to that point in time. The program breaks even when the dollars reach $0. At this point, the total benefits to participants, taxpayers, and others, are equal to the cost of the program. If the dollars are above $0, the benefits of the program exceed the initial investment. |
California Department of Corrections. (1997). Los Angeles Prison Parole Network: An evaluation report. CA: Author.
Grommon, E., Davidson, I.I. W.S., & Bynum, T.S. (2013). A randomized trial of a multimodal community-based prisoner reentry program emphasizing substance abuse treatment. Journal of Offender Rehabilitation, 52(4), 287-309.
Krebs, C.P., Strom, K.J., Koetse, W.H., & Lattimore, P.K. (2009). The impact of residential and nonresidential drug treatment on recidivism among drug-involved probationers: A survival analysis. Crime and Delinquency, 55(3), 442-471.
Martin, S.S., & Scarpitti, F.R. (1993). An intensive case management approach for paroled iv drug users. Journal of Drug Issues, 23(1), 43-59.
Zanis, D., Mulvaney, F., Coviello, D., Alterman, A., Savitz, B., & Thompson, W. (2003). The effectiveness of early parole to substance abuse treatment facilities on 24-month criminal recidivism. Journal of Drug Issues, 33(1), 223-235.